Beskrywing

The non-small cell lung cancer (NSCLC) drug market in China in terms of revenue is set to grow by US$ 13 miljard tydens 2021-2027, groei teen 'n saamgestelde jaarlikse groeikoers (CAGR) van 17.1% gedurende die voorspellingsperiode, volgens die data- en ontledingsmaatskappy StrategyHelix.

Die verslag verskaf up-to-date markgrootte data vir tydperk 2017-2020 en voorspel tot 2027 covering key market aspects like sales value for non-small cell lung cancer (NSCLC) drug. The China non-small cell lung cancer (NSCLC) drug market is segmented on the basis of type, incidence of gene mutation. Volgens tipe, it is categorized into adenocarcinoma, large cell carcinoma, sarcomatoid carcinoma, squamous-cell carcinoma, en ander. By incidence of gene mutation, the non-small cell lung cancer (NSCLC) drug market is divided into ALK (anaplastic lymphoma kinase), EGFR (epidermal growth factor receptor), KRAS (Kirsten rat sarcoma viral oncogene homologue), en ander.

The report has profiled some of the key players of the market such as AstraZeneca plc., Betta Pharmaceuticals Co. Bpk., Bristol-Myers Squibb Company, Merck KGaA, Novartis International AG, Pfizer Inc., Roche Holding AG, Takeda Pharmaceutical Co. Bpk.

Die verslag is 'n waardevolle hulpbron vir maatskappye en organisasies wat in hierdie bedryf aktief is. It provides a cohesive picture of the non-small cell lung cancer (NSCLC) drug market to help drive informed decision making for industry executives, beleidmakers, akademies, en ontleders.

Verslag Omvang

Tik: adenocarcinoma, large cell carcinoma, sarcomatoid carcinoma, squamous-cell carcinoma, en ander
Incidence of gene mutation: ALK (anaplastic lymphoma kinase), EGFR (epidermal growth factor receptor), KRAS (Kirsten rat sarcoma viral oncogene homologue), en ander
Jare oorweeg: hierdie verslag dek die tydperk 2017 aan 2027

Sleutelvoordele vir belanghebbendes

Get a comprehensive picture of the China non-small cell lung cancer (NSCLC) drug market
Bepaal groeisektore en -neigings vir belegging
Understand what the future of the non-small cell lung cancer (NSCLC) drug market in China looks like
Identifiseer die mededingende landskap en geleentheidsvenster

INHOUDSOPGAWE

1. Markdefinisie
2. Navorsingsmetodologie
3. Markdata & Outlook
3.1 Markwaarde
3.2 Markwaarde Voorspelling
4. Non-Small Cell Lung Cancer (NSCLC) Drug Market by Type
4.1 Adenocarcinoma
4.2 Large Cell Carcinoma
4.3 Sarcomatoid Carcinoma
4.4 Squamous-Cell Carcinoma
4.5 Ander
5. Non-Small Cell Lung Cancer (NSCLC) Drug Market by Incidence Of Gene Mutation
5.1 Alk (Anaplastic Lymphoma Kinase)
5.2 Egfr (Epidermal Growth Factor Receptor)
5.3 Kras (Kirsten Rat Sarcoma Viral Oncogene Homologue)
5.4 Ander
6. Maatskappy profiele
6.1 AstraZeneca plc.
6.2 Betta Pharmaceuticals Co., Bpk.
6.3 Bristol-Myers Squibb Company
6.4 Merck KGaA
6.5 Novartis International AG
6.6 Pfizer, Inc.
6.7 Roche Holding AG
6.8 Takeda Pharmaceutical Co. Bpk.
7. Bylaag
7.1 Oor StrategyHelix
7.2 Vrywaring